10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

UBE2T Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP17379b

Specification

UBE2T Antibody (C-term) Blocking Peptide - Product Information

Primary Accession Q9NPD8

UBE2T Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 29089

Other Names
Ubiquitin-conjugating enzyme E2 T, Cell proliferation-inducing gene 50 protein, Ubiquitin carrier protein T, Ubiquitin-protein ligase T, UBE2T

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

UBE2T Antibody (C-term) Blocking Peptide - Protein Information

Name UBE2T

Function
Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes monoubiquitination. Involved in mitomycin-C (MMC)-induced DNA repair. Acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and

UBE2T Antibody (C-term) Blocking Peptide - Background

The covalent conjugation of ubiquitin to proteinsregulates diverse cellular pathways and proteins. Ubiquitin istransferred to a target protein through a concerted action of aubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme(E2), such as UBE2T, and a ubiquitin ligase (E3) (Machida et al.,2006 [PubMed 16916645]).

UBE2T Antibody (C-term) Blocking Peptide - References

Ueki, T., et al. Cancer Res. 69(22):8752-8760(2009)Longerich, S., et al. J. Biol. Chem. 284(35):23182-23186(2009)Alpi, A.F., et al. Mol. Cell 32(6):767-777(2008)Hao, J., et al. Tumour Biol. 29(3):195-203(2008)Machida, Y.J., et al. Mol. Cell 23(4):589-596(2006)

catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784, PubMed:28437106). Also mediates monoubiquitination of FANCL and FANCI (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784). May contribute to ubiquitination and degradation of BRCA1 (PubMed:19887602). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11'-, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:20061386).

Cellular Location
Nucleus. Note=Accumulates to chromatin

UBE2T Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides